Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction

Conditions: PD-1; Neoadjuvant Chemoradiotherapy; Gastroesophageal Junction Cancer Interventions: Drug: PD-1inhibitor Sponsors: Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials